On Tuesday, Ingevity received an upgrade to its Relative Strength (RS) Rating, from 63 to 71.
IBD's unique rating identifies share price movement with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the last 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history shows that the best stocks often have an 80 or higher RS Rating as they launch their biggest runs. See if Ingevity can continue to rebound and hit that benchmark.
When To Sell Stocks To Lock In Profits And Minimize Losses
Ingevity is building a cup with handle with a 51.67 buy point. See if it can break out in volume at least 40% higher than normal.
While sales growth fell last quarter from -15% to -20%, EPS grew 0%, up from -9% in the previous report.
The company earns the No. 9 rank among its peers in the Chemicals-Specialty industry group. Linde, Balchem and NewMarket are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
